The debrisoquine hydroxylation test predicts steady‐state plasma levels of desipramine.
Open Access
- 1 March 1983
- journal article
- Published by Wiley in British Journal of Clinical Pharmacology
- Vol. 15 (3), 388-390
- https://doi.org/10.1111/j.1365-2125.1983.tb01518.x
Abstract
No abstract availableThis publication has 11 references indexed in Scilit:
- A double–blind study of zimelidine, a serotonin uptake inhibitor, and desipramine, a noradrenaline uptake inhibitor, in endogenous depressionActa Psychiatrica Scandinavica, 1982
- Active metabolites of imipramine and desipramine in manClinical Pharmacology & Therapeutics, 1982
- E- and Z-10-hydroxylation of nortriptyline: Relationship to polymorphic debrisoquine hydroxylationClinical Pharmacology & Therapeutics, 1981
- Pharmacogenetic covariation of defective N-oxidation of sparteine and 4-hydroxylation of debrisoquineEuropean Journal of Clinical Pharmacology, 1980
- POLYMORPHIC HYDROXYLATION OF DEBRISOQUINE IN MANThe Lancet, 1977
- Prediction of steady-state plasma levels of nortriptyline from single oral dose kinetics: A study in twinsEuropean Journal of Clinical Pharmacology, 1973
- Pharmacokinetics of desmethylimipramine and nortriptyline in man after single and multiple oral doses ? A cross-over studyEuropean Journal of Clinical Pharmacology, 1972
- A comparative study of the metabolism of desmethylimipramine, nortriptyline, and oxyphenylbutazone in manClinical Pharmacology & Therapeutics, 1969
- Plasma levels of monomethylated tricyclic antidepressants during treatment with imipramine-like compoundsLife Sciences, 1967